ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
31.92
+0.43 (1.35%)
Nov 5, 2024, 11:10 AM EST - Market open
ArriVent BioPharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 13.16 | 9.71 | 6.47 | 3.02 |
| Research & Development | 73.04 | 64.88 | 30.43 | 8.58 |
| Operating Expenses | 86.21 | 74.59 | 36.91 | 11.59 |
| Operating Income | -86.21 | -74.59 | -36.91 | -11.59 |
| Interest & Investment Income | 11.32 | 5.26 | - | - |
| EBT Excluding Unusual Items | -74.89 | -69.33 | -36.91 | -11.59 |
| Pretax Income | -74.89 | -69.33 | -36.91 | -68.81 |
| Net Income | -74.89 | -69.33 | -36.91 | -68.81 |
| Net Income to Common | -74.89 | -69.33 | -36.91 | -68.81 |
| Shares Outstanding (Basic) | 16 | 2 | 1 | 1 |
| Shares Outstanding (Diluted) | 16 | 2 | 1 | 1 |
| Shares Change (YoY) | 994.78% | 67.64% | 79.57% | - |
| EPS (Basic) | -4.69 | -32.38 | -28.90 | -96.75 |
| EPS (Diluted) | -4.69 | -32.38 | -28.90 | -96.75 |
| Free Cash Flow | -68.07 | -55.84 | -43.63 | -16.78 |
| Free Cash Flow Per Share | -4.27 | -26.08 | -34.16 | -23.60 |
| EBIT | -86.21 | -74.59 | -36.91 | -11.59 |
Source: S&P Capital IQ. Standard template.
Financial Sources.